{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:56:36Z","timestamp":1781254596923,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:02:13Z","timestamp":1773676933000},"page":"366-376.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Descriptive Study of Current Routine Clinical Practice in the Management of Patients With Multiple Myeloma in Spain: CROMMAS Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-0085","authenticated-orcid":false,"given":"Enrique M.","family":"Ocio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2026.03.004_bib0001","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2026.03.004_bib0002","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","article-title":"Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study","volume":"23","author":"Chang-Chan","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"10272","key":"10.1016\/j.clml.2026.03.004_bib0003","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clml.2026.03.004_bib0004","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2026.03.004_bib0005","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.004_bib0006","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.clml.2026.03.004_bib0007","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2026.03.004_bib0008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2026.03.004_bib0009","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.clml.2026.03.004_bib0010","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.03.004_bib0011","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.clml.2026.03.004_bib0012","first-page":"430","article-title":"Current frontline treatment of multiple myeloma","volume":"36","author":"Holstein","year":"2022","journal-title":"Oncology (Williston Park)"},{"issue":"8","key":"10.1016\/j.clml.2026.03.004_bib0013","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.03.004_bib0014","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2026.03.004_bib0015","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1182\/blood.2024027342","article-title":"Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial","volume":"145","author":"Baertsch","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.004_bib0016","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/EDBK_320129","article-title":"When and how to treat relapsed multiple myeloma","volume":"41","author":"Nathwani","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.clml.2026.03.004_bib0017","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2026.03.004_bib0018","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"issue":"2","key":"10.1016\/j.clml.2026.03.004_bib0019","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.004_bib0020","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/10428194.2022.2140283","article-title":"Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: a retrospective cohort study","volume":"64","author":"Rahman","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.03.004_bib0021","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2340\/1651-226X.2025.42647","article-title":"Evolution of treatment practices and outcomes in multiple myeloma during 2013-2022: a Finnish real world registry study","volume":"64","author":"Partanen","year":"2025","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clml.2026.03.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113921","article-title":"Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: an analysis using linked Nordic registries","volume":"201","author":"Abildgaard","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.03.004_bib0023","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/j.clml.2021.12.009","article-title":"Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study","volume":"22","author":"Abello","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"30","key":"10.1016\/j.clml.2026.03.004_bib0024","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2217\/fon-2023-0120","article-title":"Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland","volume":"19","author":"Vikkula","year":"2023","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.03.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70064","article-title":"Characteristics, treatment patterns, and outcomes of patients with multiple myeloma, including those who are triple-class exposed: a retrospective cohort study in England using national Cancer Registry data","volume":"6","author":"Tsang","year":"2025","journal-title":"eJHaem"},{"issue":"5","key":"10.1016\/j.clml.2026.03.004_bib0026","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2026.03.004_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/ph17101272","article-title":"Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: the CARINAE study","volume":"17","author":"de Arriba de la Fuente","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clml.2026.03.004_bib0028","article-title":"Treatment patterns of patients with multiple myeloma in a real-world setting in Spain. How are triple-class exposed patients being managed?","author":"Llinares","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.03.004_bib0029","article-title":"Real-world practice in the management of transplant-eligible newly diagnosed multiple myeloma: a US-based cross-sectional national survey","author":"Ali","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2026.03.004_bib0030","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14796694.2025.2460419","article-title":"Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey","volume":"21","author":"Yasutomi","year":"2025","journal-title":"Future Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.03.004_bib0031","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.03.004_bib0032","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Monika","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2026.03.004_bib0033","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2026.03.004_bib0034","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jgo.2015.03.003","article-title":"Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: the GAH Scale","volume":"6","author":"Bonanad","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.004_bib0035","article-title":"Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: the RETROGAH study","volume":"14","author":"de la","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.03.004_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133469","article-title":"The real-world evidence on the fragility and its impact on the choice of treatment regimen in newly diagnosed patients with multiple myeloma over 75 years of age","volume":"15","author":"Tyczynska","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10192","key":"10.1016\/j.clml.2026.03.004_bib0037","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2026.03.004_bib0038","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.03.004_bib0039","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.03.004_bib0040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.03.004_bib0041","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","article-title":"Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2026.03.004_bib0042","first-page":"2049","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2026.03.004_bib0043","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.clml.2026.03.004_bib0044","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.004_bib0045","first-page":"86","article-title":"Assessment and treatment of elderly patients with multiple myeloma","volume":"20","author":"de Ramon Ortiz","year":"2024","journal-title":"healthbook TIMES Onco Hema"},{"issue":"4","key":"10.1016\/j.clml.2026.03.004_bib0046","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.03.004_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2026.01.013","article-title":"An oBservational retrospective analysis of treatment patternS and effectiveness of standard of CAre for Multiple Myeloma patients exposed to lenalidomide and a proteasome inhibitor: basecaMMp study","author":"Kortum","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.clml.2026.03.004_bib0048","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clml.2024.03.003","article-title":"Characteristics and outcomes of patients with relapsed\/refractory multiple myeloma after exposure to lenalidomide in first line of therapy: a single center database review in Greece","volume":"24","author":"Kastritis","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2026.03.004_bib0049","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/j.clml.2025.01.009","article-title":"Real-world treatment patterns and outcomes in patients with lenalidomide-refractory multiple myeloma with 1 to 3 prior lines: SEER-Medicare database","volume":"25","author":"Dhakal","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:07:16Z","timestamp":1781251636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000686"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Descriptive Study of Current Routine Clinical Practice in the Management of Patients With Multiple Myeloma in Spain: CROMMAS Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}